雄激素受体抑制剂 3

• CHMP建议欧盟批准达罗鲁米特加ADT用于mHSPC 2025/06/20
• CHMP recommends EU approval of darolutamide plus ADT in mHSPC 2025/06/20
• FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC 2025/06/17